Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 16, 2024. According to the Company's Next Day Disclosure Report, the Company has repurchased millions of shares during the above period, with a detailed record of the number of shares repurchased and the date of the change. The extent of the discount or premium between the repurchase price and the market price is also disclosed. This series of share repurchases is carried out in accordance with the Listing Rules of the Hong Kong Stock Exchange Limited and the relevant rules of the Shanghai Stock Exchange. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.

Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 8 to April 16, 2024. According to the Company's Next Day Disclosure Report, the Company has repurchased millions of shares during the above period, with a detailed record of the number of shares repurchased and the date of the change. The extent of the discount or premium between the repurchase price and the market price is also disclosed. This series of share repurchases is carried out in accordance with the Listing Rules of the Hong Kong Stock Exchange Limited and the relevant rules of the Shanghai Stock Exchange. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.